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Abstract
Background & Aims: Hepatocellular adenoma (HCA) is a benign liver tumour that 
may require resection in select cases. The aim of this study was to the assess growth 
of residual HCA in the remnant liver and to advise on an evidence-based manage-
ment strategy.
Method: This multicentre retrospective cohort study included all patients with HCA 
who underwent surgery of HCA and had residual HCA in the remnant liver. Growth 
was defined as an increase of >20% in transverse diameter (RECIST criteria). Data on 
patient and HCA characteristics, diagnostic work-up, treatment and follow-up were 
documented and analysed.
Results: A total of 134 patients were included, one male. At diagnosis, median age 
was 38yrs (IQR 30.0-44.0) and median BMI was 29.9 kg/m2 (IQR 24.6-33.3). After 
resection, median number of residual sites of HCA was 3 (IQR 2-6). Follow-up of re-
sidual HCA showed regression in 24.6%, stable HCA in 61.9% and growth of at least 
one lesion in 11.2%. Three patients (2.2%) developed new HCA that were not visible 
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1  | INTRODUC TION
Hepatocellular adenoma (HCA) is a benign tumour of the liver which 
predominantly occurs in females. It is associated with the use of oral 
contraceptives (OC) or androgens, obesity and metabolic disorders 
such as glycogen storage disease (GSD) or hepatocyte nuclear fac-
tor 1a maturity-onset diabetes of the young (HNF1A-MODY).1-3 
Regression often occurs after cessation of OC and weight reduc-
tion.4-6 Several molecular HCA subtypes have been described: 
HNF-1α inactivated (H-HCA), inflammatory (I-HCA), β-catenin-
activated (β-HCA), β-catenin-activated inflammatory (β-IHCA) and 
recently sonic hedgehog (sh-HCA) adenomas.7,8 When no specific 
mutations are found, the HCA are termed as unclassified (U-HCA).
After HCA diagnosis, lifestyle adaption with cessation of OC and 
weight reduction is indicated, irrespective of HCA diameter.9 In case 
of growth or when the HCA fails to regress to less than 5cm, resec-
tion may be indicated.9,10 Other indications for resection are HCA in 
men, patients with β-HCA or β-IHCA.
Up to half of all patients with HCA present with multinodular dis-
ease which appears to be associated with a higher BMI.11,12 The risk 
of complications does not differ from those with solitary HCA; there-
fore it has been recommended to base management decisions in pa-
tients with multiple HCA on the size of the largest tumour.9 In patients 
with unilobular disease, a hemihepatectomy or segmental resection 
can be performed to resect all HCA. However, in patients with wide-
spread HCA, residual HCA may remain in situ after resection. It is 
unclear whether these HCA may grow as a result of post-resectional 
liver regeneration, as studies regarding the follow-up of residual HCA 
have been lacking from published literature. The aim of this study was 
to assess whether growth of residual HCA in the remnant liver occurs 
and to advise on an evidence-based management strategy.
2  | METHODS
This study was a multicentre retrospective cohort study performed 
in five major hepatobiliary centres in the Netherlands and Belgium 
[Erasmus MC University Medical Center Rotterdam, Amsterdam 
University Medical Centers, Location Academic Medical Center and 
Location VU Medical Center, University Medical Center Groningen 
and University Hospital KU Leuven]. All Dutch centres take part in the 
Dutch Benign Liver Tumor Group (DBLTG). Identification of eligible 
patients was done by the two first authors (AJK and BVR) performing 
a search in the electronic patient records in each participating centre, 
using the search terms benign liver tumor, hepatocellular adenoma or 
common synonyms. Additionally, all centres taking part in the DBLTG 
are required to have an updated database of the patients diagnosed 
with benign liver tumours. These databases were searched as well for 
patients with HCA. Eligible patients were those diagnosed with mul-
tiple (>1) HCA, based on either contrast-enhanced MRI, histological 
examination or both. Patients were included if they had undergone re-
section of one or more HCA and had residual sites of HCA in situ after 
resection. The minimum follow-up time after resection was 6 months.
The study protocol was reviewed by the accredited institutional 
review board; informed consent was waived.
2.1 | Data collection
Electronic medical records were reviewed for baseline patient 
characteristics: sex, age at diagnosis, BMI, comorbidity and use 
of hormonal medication were documented. Lesion characteristics 
documented were size of the largest HCA at diagnosis, number of 
on imaging prior to surgery. Four patients (3%, one male) underwent an interven-
tion as growth was progressive. No statistically significant differences in clinical char-
acteristics were found between patients with growing residual or new HCA versus 
those with stable or regressing residual HCA.
Conclusion: In patients with multiple HCA who undergo resection, growth of residual 
HCA is not uncommon but interventions are rarely needed as most lesions stabilize 
and do not show progressive growth. Surveillance is indicated when residual HCA 
show growth after resection, enabling intervention in case of progressive growth.
K E Y W O R D S
adenoma liver cell, follow-up studies, surgical procedure
KEY POINTS
• In this study we looked at patients who underwent a re-
section of hepatocellular adenoma (HCA, a benign liver 
tumour) and had residual HCA in the remnant liver.
• We investigated whether growth of these residual HCA 
occurred and found that growth is not uncommon, but 
interventions are rarely needed as most lesions stabilize 
during follow-up.
• In case these lesions do grow, follow-up is advised ena-
bling an intervention when progressive growth occurs.
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lesions and size of the residual HCA before and after resection. 
Histopathological assessment of resection specimen was per-
formed at each participating centre. HCA subtypes were deter-
mined based on histology of the resection specimen or of a liver 
biopsy. When no material for pathology was present, subtype 
differentiation was based on contrast-enhanced MRI. Subtypes 
included were H-HCA, I-HCA, β-HCA, β-IHCA and U-HCA; sh-
HCA were not included as immunohistochemical staining and 
molecular diagnosis was not yet implemented at the time of diag-
nosis of most patients. Indication for resection, type of resection 
(hemihepatectomy [at least three segments] or segmental resec-
tion [two segments or less]) and the number of resected HCA were 
documented. Complications after surgery were documented and 
graded according to the Clavien-Dindo Classification, with grade 
I and II complications classified as minor complications and grade 
III or higher as major complications. Follow-up of the residual HCA 
was based on imaging (MRI or CT), two dimensional measurements 
were performed and the largest transversal diameter was docu-
mented. Tumour growth was defined as an increase of >20% and 
HCA regression as a decrease of >30% as per RECIST criteria for 
response evaluation in solid tumours.13 The three largest residual 
tumours were assessed as index lesions for growth or regression. 
If at least one HCA showed an increase of >20% this was scored as 
growth [regardless the behaviour of the other two], if at least two 
HCAs showed a decrease of >30% and the other remained stable, 
this was scored as regression.
2.2 | Statistical analysis
For the statistical analysis, patients were divided into two subgroups: 
patients whose residual HCA showed growth or who developed new 
lesions (showing undesirable behaviour) versus those whose residual 
HCA were stable or showed regression. Continuous variables were 
summarized as median and interquartile range (IQR), categorical 
variables as frequencies (n) and percentages. Differences between 
groups were analysed using Mann-Whitney U test for continuous 
variables and chi-squared test for categorical variables. All statisti-
cal analyses were performed with SPSS software version 24.0 (IBM).
3  | RESULTS
3.1 | Clinical characteristics
A total of 134 patients were included: 48 from Erasmus MC University 
Medical Center Rotterdam, 30 from Amsterdam University Medical 
Centers, Location Academic Medical Center and six from Location 
VU Medical Center, 35 from University Medical Center Groningen 
and 15 from University Hospital KU Leuven. Patients were di-
agnosed between 1992 and 2018 [1989-1999: n = 5, 2000-2004: 
n = 15, 2005-2009: n = 42, 2010-2014: n = 51, 2015-2018: n = 21]. 
Baseline characteristics are summarized in Table 1.
3.2 | Surgical resection
All patients underwent surgical resection of HCA, median time be-
tween diagnosis and surgery was 5 months (IQR 2.0-12.0). The most 
common indication for resection was size of the HCA >50 mm (46.3%), 
followed by atypical imaging characteristics or suspected hepatocel-
lular carcinoma (HCC) (20.1%), haemorrhage (11.9%) and symptoms 
(10.4%). Other indications were growth of HCA (6.7%) after cessation 
of OC, an active pregnancy wish (3.0%), confirmed β-HCA on biopsy 
(0.7%) and male sex (0.7%). The majority was treated with a segmental 
resection (61.2%) or hemihepatectomy (32.8%), median hospital stay 
after resection was 9 days (IQR 7.0-10.0). All resections were complete 
resections. No major post-operative complications occurred, 18.7% of 
the patients suffered minor post-operative complications.
TA B L E  1   Baseline characteristics
N (%) or median (IQR)
Sex
Female 133 (99.3)
Male 1 (0.7)
Age at diagnosis (yr) 38 (30.0-44.0)
BMI (kg/m2) 29.9 (24.6-33.3)
HCA-related comorbidity
Diabetes mellitus 17 (12.7)
Glycogen storage disease 3 (2.2)
Maturity-onset diabetes of the young 2 (1.5)
Hormone usage
Oral contraceptives 116 (86.6)
None 6 (4.5)
Steroids or other hormonal medication 2 (1.5)
Unknown 10 (7.5)
Diameter of largest HCA at diagnosis (mm) 89 (69.5-110.0)
Number of HCA at diagnosis
2-5 53 (39.6)
6-10 48 (35.8)
>10 33 (24.6)
Months between resection and first 
follow-up
6 (4-9)
Diagnostic work-up
Contrast-enhanced MRI 123 (91.8)
Biopsy 48 (35.8)
HCA subtype
H-HCA 18 (13.5)
I-HCA 69 (51.5)
B-HCA 2 (1.5)
B-IHCA 3 (2.2)
U-HCA 10 (7.5)
H-HCA + I-HCA 2 (1.5)
Undetermined 30 (22.4)
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3.3 | Follow-up
Median total follow-up time was 49 months (IQR 27.0-78.0) and the 
median number of residual HCA was 3 (IQR 2-6). Median time be-
tween surgical resection and first follow-up scan was 6 months (IQR 
4-9), follow-up of residual HCA showed regression in 24.6%, stable 
lesions in 61.9%, growth in 11.2% and in 2.2% new lesions were ob-
served that were not visible on imaging prior to resection. No haem-
orrhage occurred in the residual HCA during follow-up.
No statistically significant differences between patients 
whose residual HCA showed growth or who developed new le-
sions versus those whose residual HCA were stable or showed 
regression were found for BMI, age at diagnosis, number of resid-
ual HCA, HCA-related comorbidity, HCA subtype and resection 
type (Table 2).
Among the 18 patients with growing or new lesions, 14 were 
treated conservatively. In these patients, growth was diagnosed 
at the first follow-up imaging after resection, all lesions remained 
<50 mm and the majority stabilized within 2 years of follow-up. 
Four patients (3%, three females and one male) underwent inter-
vention for growing residual HCA. Of the females, the first patient 
underwent transarterial embolization (TAE), the second under-
went two re-resections and the third patient underwent both 
re-resection as well as TAE for growing residual HCA (Figure 1). 
None of these patients had HCA-related comorbidity and no dys-
plasia or transformation to HCC was found in these patients. The 
only male patient included in this study, known with non-cirrhotic 
portal hypertension and diagnosed with β-IHCA, underwent ra-
diofrequency ablation (RFA) for a new HCA and is currently on 
the waiting list for liver transplantation because of multiple new 
and progressively growing HCA as depicted by contrast-enhanced 
MRI. Histopathological examination of the resection specimen 
confirmed HCA in all four patients. In one patient with a residual 
HCA of 15 mm, follow-up after resection showed complete regres-
sion after resection as depicted by contrast-enhanced MRI. She 
then restarted her OC and the residual HCA grew to 60mm. After 
cessation of OC, the residual HCA regressed completely again 
(Figure 2).
4  | DISCUSSION
HCA may require resection in selected cases. In patients with 
many and widespread HCA, residual sites of HCA may remain in 
situ after resection. It is unclear whether these lesions may grow 
as a result of liver regeneration after resection. This retrospec-
tive cohort study including 134 patients evaluated whether in 
patients with multiple HCA, growth of residual HCA in the rem-
nant liver occurs and to advise on an evidence-based manage-
ment strategy.
In this study, growth or new HCA was a reason for intervention 
in 3.0% of patients. Reasons for intervention in cases with growing 
Growing/new lesions
n = 18
N (%) or median (IQR)
Stable/regressing lesions
n = 116
N (%) or median (IQR) P-value
BMI (kg/m2) 26.4 (23.7-30.5) 30.1 (24.8-33.6) .169
Age at diagnosis (yr) 41 (33.3-44.3) 38 (29.3-44.0) .579
Number of residual 
HCA
2 (1.5-5) 3 (2-6) .339
HCA-related comorbidity
Diabetes mellitus 0 (0) 17 (14.7) .136
GSD 0 (0) 3 (2.6)
MODY-3 0 (0) 2 (1.7)
HCA subtype
H-HCA 2 (10.5) 16 (14.0) .291
I-HCA 10 (55.6) 59 (50.9)
B-HCA 0 (0) 2 (1.7)
B-IHCA 2 (10.5) 1 (0.9)
U-HCA 0 (0) 10 (8.6)
H-HCA + I-HCA 0 (0) 2 (1.7)
Undetermined 4 (22.2) 26 (22.4)
Primary resection type
Segment resection 8 (44.4) 74 (63.8) .098
Hemihepatectomy 10 (55.6) 34 (29.3)
Enucleation 0 8 (6.9)
TA B L E  2   Growing or new lesions vs 
stable or regressing lesions
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residual lesions were either an increase to >50 mm or progressive 
growth without stabilization of the lesion. One of these patients 
was a male with growing and new HCA who is still under surveil-
lance because of progressive growth. Although this patient was 
diagnosed with HCA based on histopathological examination, the 
new and progressively growing lesions suggest that the diagnosis 
might also be well-differentiated HCC. It may be very difficult to 
distinguish HCA from well-differentiated HCC, even for expert 
pathologists.14-16
In one patient with a residual HCA, follow-up after resection 
showed complete regression after resection as depicted by con-
trast-enhanced MRI. After she restarted her OC, the residual HCA 
showed growth. Complete regression occurred again after cessation 
of OC. This suggests that patients with HCA might have a lifelong 
contraindication for the use of OC, even if no residual HCA is present 
after resection or complete regression of residual HCA has occurred.
Regression of residual HCA could either still be a result of ces-
sation of OC or a result of weight loss or menopause, but might also 
be explained by the altered tumour regulation of the tissue environ-
ment in the liver with resection of the largest lesion(s). It has been 
established that this tumour regulation of the tissue environment 
plays a role in tumour formation and tumour growth in HCC in cir-
rhotic livers.17 Unfortunately, the latter is still unexplored territory 
in the field of HCA. An interesting group to study regarding tumour 
environment of HCA would be patients with multiple tumours, who 
have undergone TAE or RFA for the largest tumour, since liver re-
generation caused by increased portal flow plays no role in these 
patients.
Although the authors realize that a minimum follow-up time of 
6 months might seem short, we have chosen this follow-up period 
consciously. After resection, liver regeneration occurs within the first 
weeks as a result of an increased flow to the remnant liver causing an 
F I G U R E  1   Cases with growing residual HCA requiring intervention. HCA, hepatocellular adenoma; Preop, pre-operative; Yr, number of 
years post-operative; Mo, number of months post-operative; OC, oral contraceptive; TAE, transarterial embolization. (A) Female patient with 
multiple residual HCA who underwent a re-resection 12 and 14 years after the first resection because of progressively growing residual 
HCA. (B) Female patient with multiple residual HCA who underwent transarterial embolization and re-resection 5 and 6 years after the 
first resection because of progressively growing residual HCA. (C) Female patient with single residual HCA who underwent transarterial 
embolization 5 years after resection because of progressively growing HCA. (D) Male patient with β-catenin-mutated HCA, who underwent 
radiofrequency ablation 6 months after resection because of one new HCA. Patient still has multiple new growing lesions and is currently on 
the waiting list for liver transplantation
F I G U R E  2   Case demonstrating the effect of oral contraceptive 
on HCA. Female patient with single residual HCA that showed 
complete regression after resection. When OC was restarted, 
the lesion showed progressive growth. It regressed again after 
cessation of OC
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increase in growth factors.18 Therefore, growth of residual HCA can 
be expected in the first period after resection. The flow and levels 
of growth factors stabilize after the first period and any growth of 
residual HCA is more likely attributed to the natural course of the 
disease and not a result of liver regeneration after resection.
In this cohort, factors predictive of growth of residual HCA could 
not be identified. BMI, age at diagnosis, resection type, number of 
residual HCA, HCA-related comorbidity and HCA subtype were con-
sidered to be clinically relevant, but no statistically significant differ-
ences were found between patients whose residual HCA showed 
growth or who developed new lesions versus those whose residual 
HCA were stable or showed regression. Ideally, change in BMI would 
have been added as a potential predictive variable, as weight loss 
seems to be related to regression of HCA and therefore weight gain 
may induce growth.19 Unfortunately, in the participating centres, 
change in BMI was underreported. No difference in growth rate was 
demonstrated between patients who underwent hemihepatectomy 
versus those who underwent segmental resection or enucleation. As 
liver regeneration increases with a larger resected hepatic volume, a 
difference might have been expected. Additionally, no differences 
were found for HCA subtype while there has been a difference 
found for HCA regression in different subtypes.20 The lack of statis-
tically significant differences may well be attributed to the relatively 
small sample size.
In this study, almost a quarter of patients had >10 HCA and could 
be defined as liver adenomatosis. Recently, a study was published 
describing the long-term follow-up of 40 patients with liver adeno-
matosis.21 In their cohort, 93% of the patients underwent surgery 
and 23% of the patients harboured a new lesion or showed growth 
of residual HCA. This lead to a surgical resection in 10%. In our study 
these percentages are lower, which might be attributed to the larger 
study group. Additionally, these authors described that the hetero-
geneous nature of liver adenomatosis justifies close and specific 
management, although complications (haemorrhage and malignant 
transformation) did not seem to occur more often than in patients 
with <10 HCA.21 The heterogeneous nature underlines the prevail-
ing thought that management of HCA should be based on HCA sub-
type and less on the number of HCA.9
The current study is the first to report on the management of 
residual HCA after hepatic resection in a large, multicentre cohort 
with long follow-up. The multicentre design offers advantages of 
an increase in statistical power and generalizability of the results. 
Inevitably, it is also subject to some limitations. First of all, the study 
may be subject to selection bias as we only included patients from 
expertise centres. Patients showing growth of residual HCA after 
resection might be referred to an expertise centre more often than 
patients with stable or regression lesions. Therefore the percentage 
of patients with growing residual HCA may be lower than seen in 
this study. Secondly, patients were included during a long period 
with five patients diagnosed even before 2000. All of these patients 
were diagnosed at an early age and followed for at least 20 years. 
Additionally, all HCA were proven on histopathological examination. 
A third limitation might lie in the fact that transversal measurements 
were used to assess tumour growth or regression as per RECIST cri-
teria, and that the exact regeneration volume of the remnant liver 
was not measured. However, the authors believe that using trans-
versal measurements reflects clinical practice. Finally, one might be 
that only one male patient was included. However, in the participat-
ing centres, males usually undergo treatment for all HCA given the 
higher risk of malignant transformation and therefore do not have 
any residual HCA after resection.
In conclusion, this study shows that growth of residual HCA is 
not uncommon and interventions are rarely needed as most lesions 
stabilize and do not show progressive growth. Follow-up of residual 
HCA should be performed after surgery. When residual HCA show 
growth after resection, patients should be kept under surveillance 
for at least 2 years, after that the majority stabilizes. It would be ad-
visable to schedule the first follow-up scan 3-6 months after surgical 
resection and repeat imaging every 6-12 months until regression or 
stabilization occurs. An intervention such as TAE or RFA for small 
HCA or re-resection in large or atypical residual HCA may be consid-
ered in case of progressive growth and if lifestyle advices (cessation 
of OC and weight loss) fail to cause stabilization or regression.
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